| |JULY 20249ANTIDOTE & SEQSTER JOIN HANDS TO ADVANCE PATIENT IDENTIFICATIONLIGAND PHARMA TO ACQUIRE APEIRON BIOLOGICS FOR $ 100 MILLIONAntidote Technologies, a digital health firm that focuses on patient engagement to advance recruitment for clinical trials, and SEQSTER PDM Inc., the leading patient-centric healthcare technology company, declared an agreement to improve patient identification, trial timelines, and enrollment outcomes for Pharma and Life Science organizations with their fully integrated end-to-end solution.Antidote can better match patients to clinical trials based on a 360-degree view of their medical history, genomic data, and lifestyle factors by utilizing the SEQSTER Operating System. Combining Antidote's best-in-class screening and patient support services with this solution enables faster recruitment of higher-quality patients and a more precise match for potential clinical trials for which they may qualify."By integrating SEQSTER's Operating System with Antidote's precision recruitment capabilities, we are creating a powerful synergy that addresses one of the most pressing challenges in clinical research today: clinical trial recruitment plus engagement. This partnership empowers us to accelerate patient recruitment while providing a comprehensive, real-time view of study participant health data, accelerating the path to medical breakthroughs," stated Ardy Arianpour, CEO & Co-Founder of SEQSTER."Our mission at Antidote has always been to connect the right patients with the right trials, striking a balance between advanced technology and a personal touch. Partnering with SEQSTER allows us to enhance our precision recruitment process with unparalleled data integration capabilities, ensuring that we can more effectively identify suitable participants and reduce the time it takes to bring new treatments to market. Together with SEQSTER, we will transform the clinical trial landscape, making it more efficient, inclusive, and patient-centered," explained Samantha Veeck, Co-CEO of Antidote. POLigand Pharmaceuticals, a biopharmaceutical company, delcared that it has forayed into a definitive contract to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA® (dinutuximab beta) for the treatment of high-risk neuroblastoma, for $ 100 million in cash. Also, Ligand will pay APEIRON shareholders extra consideration based on future commercial and regulatory events, including up to $ 28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively.APEIRON is a private biopharmaceutical organization situated in Vienna, Austria. For the treatment of high-risk neuroblastoma in patients over the age of twelve, the company co-developed QARZIBA and was endorsed by the European Prescriptions Organization in 2017 and is commercially accessible today in excess of 35 nations. Recordati S.p.A., a leading global pharmaceutical company with a presence in over 150 countries and sales of more than $2.2 billion2, and BeiGene, each pay APEIRON an undisclosed royalty on net sales of QARZIBA outside of mainland China."The addition of QARZIBA to our commercial royalty portfolio further supports our growth strategy to invest in high-value medicines that deliver significant clinical value and generate predictable and long-term revenue streams for our investors," said Todd Davis, CEO of Ligand. "QARZIBA is the only immunotherapy for high-risk neuroblastoma marketed across Europe and in other parts of the world. We believe this drug will be a meaningful contributor to our royalty revenue, which is now driven by a diversified portfolio of 12 key commercial-stage products." PO
< Page 8 | Page 10 >